PDS Biotechnology Corporation

PDS Biotechnology Corporation

PDSB - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$48.57M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
PDS Biotechnology CorporationPDS Biotechnology Corporation-1.4-1%--1.2
$4.00

Target Price by Analysts

358.4% upsidePDS Biotechnology Target Price DetailsTarget Price
$0.21

Current Fair Value

75.8% downside

Overvalued by 75.8% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$48.57 Million
Enterprise Value$-1,184,013,373.00
Earnings per Share$-0.74
Beta1.45
Outstanding Shares55,659,669

Return

Return on Equity1.01%ROE
Return on Assets-0.41%
Return on Invested Capital228.54%

Valuation & Multiples

P/E Ratio-1.36P/E Ratio
PEG-40.66PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.01Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT0.15
Enterprise Value to Net Income32
Total Debt to Enterprise-3.58
Debt to Equity-1.22Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 13, 2026
EPS
-$0.11
Est. -$0.09
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
March 29, 2027
EPS Estimate
-$0.07
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 1.69, the ratio is above 1, so institutions hold more puts than calls. That is a more cautious stance.

Put/Call Ratio1.6857▲ 168.57%
Total Calls49,000▼ 85.74%
Total Puts82,600▲ Infinity%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %16.39%▲ 2.57%
Total Invested$6.84M▲ 0.96%
Investors Holding45▼ 8.00%

About PDS Biotechnology Corporation

CEO: Frank Bedu-Addo

Under normal circumstances, the fund will invest at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities and derivative instruments that provide exposure to equity securities. To gain this exposu...

PDS Biotechnology Insider Information FAQ

Stockcircle tracks 3 top investors with a current 13F position in PDS Biotechnology. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor increased or opened positions among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.